Subcutaneous vs. intravenous application of trastuzumab in neoadjuvant setting in breast cancer HER2+ patient stage I-III, HannaH trial

Abstract

Summary - Comment on the study - Subcutaneous vs. intravenous application of trastuzumab in neoadjuvant setting in breast cancer HER2+ patient stage I-III, HannaH trial.

Keywords

• Trastuzumab
• breast cancer
• metastasis
• infusion